Company news

StemRIM Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Presentation Material for Business Plan and Growth Potential

October 30, 2026

Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa

October 7, 2026

Patent Registration in South Korea for Redasemtide in Cartilage Disorders

September 25, 2026

StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees

September 10, 2026

StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees

September 9, 2026

StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea

August 3, 2026

StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders

July 22, 2026

StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction

July 13, 2026

StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in,South Korea

July 8, 2026

[Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)

June 18, 2026

StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders

June 17, 2026

StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis

June 16, 2026

Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]

June 10, 2026

Decks

The 5 newest of 8 decks. Every deck is listed under its year.